Pure Bioscience Stock Performance
| PURE Stock | USD 0.05 0 3.53% |
The company holds a Beta of -0.65, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Pure Bioscience are expected to decrease at a much lower rate. During the bear market, Pure Bioscience is likely to outperform the market. At this point, Pure Bioscience has a negative expected return of -0.11%. Please make sure to check Pure Bioscience's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Pure Bioscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Pure Bioscience has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
| Begin Period Cash Flow | 2.5 M | |
| Total Cashflows From Investing Activities | -81 K |
Pure |
Pure Bioscience Relative Risk vs. Return Landscape
If you would invest 6.00 in Pure Bioscience on November 2, 2025 and sell it today you would lose (1.35) from holding Pure Bioscience or give up 22.5% of portfolio value over 90 days. Pure Bioscience is currently does not generate positive expected returns and assumes 7.8936% risk (volatility on return distribution) over the 90 days horizon. In different words, 70% of otc stocks are less volatile than Pure, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pure Bioscience Target Price Odds to finish over Current Price
The tendency of Pure OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.05 | 90 days | 0.05 | about 74.42 |
Based on a normal probability distribution, the odds of Pure Bioscience to move above the current price in 90 days from now is about 74.42 (This Pure Bioscience probability density function shows the probability of Pure OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Pure Bioscience has a beta of -0.65 indicating as returns on the benchmark increase, returns on holding Pure Bioscience are expected to decrease at a much lower rate. During a bear market, however, Pure Bioscience is likely to outperform the market. Additionally Pure Bioscience has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Pure Bioscience Price Density |
| Price |
Predictive Modules for Pure Bioscience
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Pure Bioscience. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Pure Bioscience Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Pure Bioscience is not an exception. The market had few large corrections towards the Pure Bioscience's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Pure Bioscience, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Pure Bioscience within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.53 | |
β | Beta against Dow Jones | -0.65 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.08 |
Pure Bioscience Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Pure Bioscience for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Pure Bioscience can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Pure Bioscience generated a negative expected return over the last 90 days | |
| Pure Bioscience has high historical volatility and very poor performance | |
| Pure Bioscience has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 41.0% of the company outstanding shares are owned by corporate insiders |
Pure Bioscience Fundamentals Growth
Pure OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Pure Bioscience, and Pure Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pure OTC Stock performance.
| Return On Equity | -1.29 | |||
| Return On Asset | -0.62 | |||
| Profit Margin | (2.02) % | |||
| Operating Margin | (1.98) % | |||
| Current Valuation | 13.51 M | |||
| Shares Outstanding | 111.36 M | |||
| Price To Earning | 12.49 X | |||
| Price To Book | 3.85 X | |||
| Price To Sales | 8.00 X | |||
| Revenue | 1.85 M | |||
| EBITDA | (3.27 M) | |||
| Cash And Equivalents | 511 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 239 K | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (2.42 M) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 4.48 M | |||
| Retained Earnings | (103.22 M) | |||
| Current Asset | 6.14 M | |||
| Current Liabilities | 2.54 M | |||
About Pure Bioscience Performance
By analyzing Pure Bioscience's fundamental ratios, stakeholders can gain valuable insights into Pure Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Pure Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pure Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California. PURE BIOSCIENCE operates under Household Personal Products classification in the United States and is traded on OTC Exchange. It employs 10 people.Things to note about Pure Bioscience performance evaluation
Checking the ongoing alerts about Pure Bioscience for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Pure Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pure Bioscience generated a negative expected return over the last 90 days | |
| Pure Bioscience has high historical volatility and very poor performance | |
| Pure Bioscience has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 1.85 M. Net Loss for the year was (3.49 M) with profit before overhead, payroll, taxes, and interest of 1000 K. | |
| Pure Bioscience currently holds about 511 K in cash with (2.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 41.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pure Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pure Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Pure Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pure Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pure Bioscience's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Pure Bioscience's otc stock. These opinions can provide insight into Pure Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Pure OTC Stock analysis
When running Pure Bioscience's price analysis, check to measure Pure Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pure Bioscience is operating at the current time. Most of Pure Bioscience's value examination focuses on studying past and present price action to predict the probability of Pure Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pure Bioscience's price. Additionally, you may evaluate how the addition of Pure Bioscience to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| AI Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |